来自条件化巨细胞和乳腺癌细胞的细胞外囊泡之间的细胞间通信驱动了内分泌疗法耐药性的驱动
María C Rodriguez-Baili1, Miguel Palma-Cobo2, César G Prucca1
1Departamento de Química Biológica Ranwel Caputto, Facultad de Ciencias Químicas, CONICET, Universidad Nacional de Córdoba-CIQUIBIC, Córdoba, Argentina.
Frontiers in cell and developmental biology
|June 26, 2025
概括
巨细胞衍生的细胞外囊泡 (EVs) 通过增加癌症干细胞特性和驱动免疫抑制,促进雌激素受体阳性乳腺癌的内分泌耐药性. 针对这些EV可能为乳腺癌患者提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 免疫学 免疫学 免疫学
背景情况:
- 雌激素受体阳性 (ER+) 乳腺癌是妇女死亡的主要原因.
- 内分泌疗法耐药性,通常是由癌症干细胞 (CSC) 驱动的,限制了治疗疗效.
- 瘤微环境 (TME),包括巨细胞和细胞外囊泡 (EV),影响瘤的进展和抵抗.
研究的目的:
- 调查巨细胞衍生的EVs在促进ER+乳腺癌内分泌耐药性的作用.
- 评估TNF-α受条件的巨EVs对乳腺癌细胞增殖,迁移,上皮细胞-介质细胞过渡 (EMT) 和CSC类属性的影响.
- 评估瘤衍生的EVs对巨细胞两极分化和免疫调节的影响.
主要方法:
- 从TNF-α条件化巨细胞 (TNF EVs) 中隔离EVs.
- 用TNF EVs治疗MCF-7 ER+乳腺癌细胞.
- 评估细胞变化 (增殖,迁移,EMT,CSC标记物,他莫西芬耐药性) 和巨细胞极化 (PD-1表达).
主要成果:
- 用TNF EV治疗的乳腺癌细胞表现出增加的增殖,迁移和EMT.
- 细胞具有类似干细胞的特性 (CD44High/CD24Low亚种群,球形形成) 和对他莫西芬的耐药性.
- 来自瘤的EV诱导了巨细胞偏向向瘤相关巨细胞 (TAM) 形状,增加PD-1表达,表明免疫抑制.
结论:
- 巨细胞衍生的EV在ER+乳腺癌中起着双重作用,驱动内分泌抵抗和免疫调节.
- EVs促进干性,EMT和他莫西芬耐药性,有助于瘤的进展.
- 针对EV介导的沟通提供了一个潜在的治疗策略,以克服抵抗并改善结果.
相关概念视频
Autocrine Signaling
48.8K
Autocrine signaling is one of the many signaling mechanisms that function inside multicellular organisms to carry out intercellular communication. In this type of signaling mechanism, the same cell that secretes an extracellular signaling molecule also expresses the receptors to bind and respond to that signaling molecule.
Autocrine Signaling in Macrophages
Under normal physiological conditions, autocrine signaling is essential for maintaining homeostasis. This process is well characterized in...
Autocrine Signaling in Macrophages
Under normal physiological conditions, autocrine signaling is essential for maintaining homeostasis. This process is well characterized in...
48.8K
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Metastasis
5.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K
Cancer Stem Cells and Tumor Maintenance
5.1K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K


